Nucleic Acid Drugs - Global Top Players Market Share and Ranking 2025- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > Nucleic Acid Drugs - Global Top Players Market Share and Ranking 2025

Nucleic Acid Drugs - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-10-13
Report Id: 2507881
Industry: Pharma & Healthcare
Report Page: 109
Chart: 107

PDF Download

Publication Date: 2025-10-13
Report Id: 2507881
Industry: Pharma & Healthcare
Report Page: 109
Chart: 107

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Nucleic Acid Drugs Definition
1.2 Global Nucleic Acid Drugs Market Size and Forecast
1.3 China Nucleic Acid Drugs Market Size and Forecast
1.4 Share of China Nucleic Acid Drugs Market with Respect to the Global Market
1.5 Nucleic Acid Drugs Market Size: China VS Global Growth Rate, 2020-2031
1.6 Nucleic Acid Drugs Market Dynamics
1.6.1 Nucleic Acid Drugs Market Drivers
1.6.2 Nucleic Acid Drugs Market Restraints
1.6.3 Nucleic Acid Drugs Industry Trends
1.6.4 Nucleic Acid Drugs Industry Policy

2 Global Leading Players and Market Share
2.1 By Revenue of Nucleic Acid Drugs, Global Market Share by Company, 2020-2025
2.2 Global Nucleic Acid Drugs Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Nucleic Acid Drugs Concentration Ratio
2.4 Global Nucleic Acid Drugs Mergers & Acquisitions, Expansion Plans
2.5 Global Nucleic Acid Drugs Major Companies Product Type
2.6 Head Office and Area Served of Key Players

3 China Leading Players, Market Share and Ranking
3.1 By Revenue of Nucleic Acid Drugs, China Market Share by Company, 2020-2025
3.2 China Nucleic Acid Drugs Nucleic Acid Drugs Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis
4.1 Nucleic Acid Drugs Industry Chain
4.2 Nucleic Acid Drugs Upstream Analysis
4.2.1 Nucleic Acid Drugs Core Raw Materials
4.2.2 Main Manufacturers of Nucleic Acid Drugs Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Nucleic Acid Drugs Production Mode
4.6 Nucleic Acid Drugs Procurement Model
4.7 Nucleic Acid Drugs Industry Sales Model and Sales Channels
4.7.1 Nucleic Acid Drugs Sales Model
4.7.2 Nucleic Acid Drugs Typical Distributors

5 Sights by Type
5.1 Nucleic Acid Drugs Classification by Type
5.1.1 Antisense Oligonucleotides (ASO)
5.1.2 siRNA
5.1.3 mRNA
5.1.4 Other
5.2 by Type, Global Nucleic Acid Drugs Consumption Value & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Nucleic Acid Drugs Consumption Value, 2020-2031

6 Sights by Application
6.1 Nucleic Acid Drugs Segment by Application
6.1.1 Neuromuscular Diseases
6.1.2 hATTR
6.1.3 COVID-19
6.1.4 Other
6.2 by Application, Global Nucleic Acid Drugs Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Application, Global Nucleic Acid Drugs Consumption Value, 2020-2031

7 Sales Sights by Region
7.1 By Region, Global Nucleic Acid Drugs Consumption Value, 2020 VS 2024 VS 2031
7.2 By Region, Global Nucleic Acid Drugs Consumption Value, 2020-2031
7.3 North America
7.3.1 North America Nucleic Acid Drugs Market Size & Forecasts, 2020-2031
7.3.2 By Country, North America Nucleic Acid Drugs Market Size Market Share
7.4 Europe
7.4.1 Europe Nucleic Acid Drugs Market Size & Forecasts, 2020-2031
7.4.2 By Country, Europe Nucleic Acid Drugs Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Nucleic Acid Drugs Market Size & Forecasts, 2020-2031
7.5.2 By Country/Region, Asia Pacific Nucleic Acid Drugs Market Size Market Share
7.6 South America
7.6.1 South AmericaNucleic Acid Drugs Market Size & Forecasts, 2020-2031
7.6.2 By Country, South America Nucleic Acid Drugs Market Size Market Share
7.7 Middle East & Africa

8 Sales Sights by Country Level
8.1 By Country, Global Nucleic Acid Drugs Market Size & CAGR, 2020 VS 2024 VS 2031
8.2 By Country, Global Nucleic Acid Drugs Consumption Value, 2020-2031
8.3 United States
8.3.1 United States Nucleic Acid Drugs Market Size, 2020-2031
8.3.2 by Type, United States Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.3.3 by Application, United States Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.4 Europe
8.4.1 Europe Nucleic Acid Drugs Market Size, 2020-2031
8.4.2 by Type, Europe Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.4.3 by Application, Europe Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.5 China
8.5.1 China Nucleic Acid Drugs Market Size, 2020-2031
8.5.2 by Type, China Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.5.3 by Application, China Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.6 Japan
8.6.1 Japan Nucleic Acid Drugs Market Size, 2020-2031
8.6.2 by Type, Japan Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.6.3 by Application, Japan Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.7 South Korea
8.7.1 South Korea Nucleic Acid Drugs Market Size, 2020-2031
8.7.2 by Type, South Korea Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.7.3 by Application, South Korea Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.8 Southeast Asia
8.8.1 Southeast Asia Nucleic Acid Drugs Market Size, 2020-2031
8.8.2 by Type, Southeast Asia Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.8.3 by Application, Southeast Asia Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.9 India
8.9.1 India Nucleic Acid Drugs Market Size, 2020-2031
8.9.2 by Type, India Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.9.3 by Application, India Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.10 Middle East & Africa
8.10.1 Middle East & Africa Nucleic Acid Drugs Market Size, 2020-2031
8.10.2 by Type, Middle East & Africa Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031
8.10.3 by Application, Middle East & Africa Nucleic Acid Drugs Consumption Value Market Share, 2024 VS 2031

9 Company Profile
9.1 Sarepta Therapeutics
9.1.1 Sarepta Therapeutics Company Information, Head Office, Market Area, and Industry Position
9.1.2 Sarepta Therapeutics Company Profile and Main Business
9.1.3 Sarepta Therapeutics Nucleic Acid Drugs Models, Specifications, and Application
9.1.4 Sarepta Therapeutics Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.1.5 Sarepta Therapeutics Recent Developments
9.2 Ionis Pharmaceuticals
9.2.1 Ionis Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
9.2.2 Ionis Pharmaceuticals Company Profile and Main Business
9.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Models, Specifications, and Application
9.2.4 Ionis Pharmaceuticals Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.2.5 Ionis Pharmaceuticals Recent Developments
9.3 Alnylam
9.3.1 Alnylam Company Information, Head Office, Market Area, and Industry Position
9.3.2 Alnylam Company Profile and Main Business
9.3.3 Alnylam Nucleic Acid Drugs Models, Specifications, and Application
9.3.4 Alnylam Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.3.5 Alnylam Recent Developments
9.4 Biogen
9.4.1 Biogen Company Information, Head Office, Market Area, and Industry Position
9.4.2 Biogen Company Profile and Main Business
9.4.3 Biogen Nucleic Acid Drugs Models, Specifications, and Application
9.4.4 Biogen Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.4.5 Biogen Recent Developments
9.5 Nippon Shinyaku
9.5.1 Nippon Shinyaku Company Information, Head Office, Market Area, and Industry Position
9.5.2 Nippon Shinyaku Company Profile and Main Business
9.5.3 Nippon Shinyaku Nucleic Acid Drugs Models, Specifications, and Application
9.5.4 Nippon Shinyaku Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.5.5 Nippon Shinyaku Recent Developments
9.6 Sobi
9.6.1 Sobi Company Information, Head Office, Market Area, and Industry Position
9.6.2 Sobi Company Profile and Main Business
9.6.3 Sobi Nucleic Acid Drugs Models, Specifications, and Application
9.6.4 Sobi Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.6.5 Sobi Recent Developments
9.7 Novartis
9.7.1 Novartis Company Information, Head Office, Market Area, and Industry Position
9.7.2 Novartis Company Profile and Main Business
9.7.3 Novartis Nucleic Acid Drugs Models, Specifications, and Application
9.7.4 Novartis Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.7.5 Novartis Recent Developments
9.8 BioNTech
9.8.1 BioNTech Company Information, Head Office, Market Area, and Industry Position
9.8.2 BioNTech Company Profile and Main Business
9.8.3 BioNTech Nucleic Acid Drugs Models, Specifications, and Application
9.8.4 BioNTech Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.8.5 BioNTech Recent Developments
9.9 Pfizer
9.9.1 Pfizer Company Information, Head Office, Market Area, and Industry Position
9.9.2 Pfizer Company Profile and Main Business
9.9.3 Pfizer Nucleic Acid Drugs Models, Specifications, and Application
9.9.4 Pfizer Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.9.5 Pfizer Recent Developments
9.10 Moderna Therapeutics
9.10.1 Moderna Therapeutics Company Information, Head Office, Market Area, and Industry Position
9.10.2 Moderna Therapeutics Company Profile and Main Business
9.10.3 Moderna Therapeutics Nucleic Acid Drugs Models, Specifications, and Application
9.10.4 Moderna Therapeutics Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.10.5 Moderna Therapeutics Recent Developments
9.11 Jazz Pharmaceuticals
9.11.1 Jazz Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
9.11.2 Jazz Pharmaceuticals Company Profile and Main Business
9.11.3 Jazz Pharmaceuticals Nucleic Acid Drugs Models, Specifications, and Application
9.11.4 Jazz Pharmaceuticals Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.11.5 Jazz Pharmaceuticals Recent Developments
9.12 Novo Nordisk
9.12.1 Novo Nordisk Company Information, Head Office, Market Area, and Industry Position
9.12.2 Novo Nordisk Company Profile and Main Business
9.12.3 Novo Nordisk Nucleic Acid Drugs Models, Specifications, and Application
9.12.4 Novo Nordisk Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.12.5 Novo Nordisk Recent Developments
9.13 AstraZeneca
9.13.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
9.13.2 AstraZeneca Company Profile and Main Business
9.13.3 AstraZeneca Nucleic Acid Drugs Models, Specifications, and Application
9.13.4 AstraZeneca Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.13.5 AstraZeneca Recent Developments
9.14 Astellas Pharma
9.14.1 Astellas Pharma Company Information, Head Office, Market Area, and Industry Position
9.14.2 Astellas Pharma Company Profile and Main Business
9.14.3 Astellas Pharma Nucleic Acid Drugs Models, Specifications, and Application
9.14.4 Astellas Pharma Nucleic Acid Drugs Revenue and Gross Margin, 2020-2025
9.14.5 Astellas Pharma Recent Developments

10 Conclusion

11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer

According to YH Research, the global market for Nucleic Acid Drugs should grow from US$ 15562 million in 2024 to US$ 22514 million by 2031, with a CAGR of 7.1% for the period of 2025-2031.

Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes. Nucleic acid drugs are being developed as novel therapeutic modalities. They have great potential to treat human diseases such as cancers, viral infections, and genetic disorders due to unique characteristics that make it possible to approach undruggable targets using classical small molecule or protein/antibody-based biologics. Currently, mRNA vaccines, small interfering RNA (siRNA, small interfering RNA) and antisense nucleic acids (ASO, antisense oligodeoxyncleotides) are the main forms of nucleic acid drug development in clinical practice.

Nucleic Acid Drugs

According to YH Research, the global market for Nucleic Acid Drugs should grow from US$ 15562 million in 2024 to US$ 22514 million by 2031, with a CAGR of 7.1% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The nucleic acid drugs market is primarily driven by the increasing understanding of genetic and molecular mechanisms underlying diseases, leading to the development of targeted therapies. Breakthroughs in genomics, such as the Human Genome Project, have enabled the identification of specific genes and genetic mutations associated with various diseases, spurring the development of nucleic acid-based treatments. Additionally, the growing demand for personalized medicine, where therapies are tailored to an individual's genetic profile, is propelling the adoption of nucleic acid drugs. Moreover, advancements in drug delivery technologies, including nanoparticles and viral vectors, are enhancing the effectiveness and safety of these therapies, further driving market growth.

Despite the promising potential of nucleic acid drugs, several challenges exist in the market. One significant challenge is the efficient delivery of nucleic acids to target cells and tissues, as they are often susceptible to degradation and immune responses. Off-target effects, such as unintended genetic alterations, and safety concerns are also important challenges that require rigorous clinical testing and validation. Additionally, the high development costs and lengthy regulatory processes for nucleic acid drugs pose financial and time-related challenges for pharmaceutical companies. Ensuring long-term stability, scalability, and cost-effectiveness of manufacturing these complex biologics is another key challenge in the market.

The future development of nucleic acid drugs is expected to be defined by technological innovation, delivery optimization, and expanding therapeutic applications beyond rare genetic diseases. Over the next decade, the field will likely transition from niche indications toward broader clinical use, driven by the maturation of RNA interference (RNAi), antisense oligonucleotides (ASOs), mRNA therapies, aptamers, and gene-editing platforms. A major focus will be on improving delivery systems—particularly ligand-conjugated and lipid nanoparticle (LNP) technologies—that enable precise targeting of extrahepatic tissues such as the central nervous system, muscle, and tumor microenvironments. Advances in chemical modification and backbone engineering are expected to enhance molecular stability, reduce immunogenicity, and prolong duration of action, making nucleic acid drugs more suitable for chronic conditions. Moreover, the integration of AI-driven sequence design and bioinformatics will accelerate candidate optimization and personalized drug development, leading to faster, more cost-effective R&D pipelines. In parallel, the commercial and regulatory landscape for nucleic acid drugs is becoming more favorable. Increasing numbers of successful approvals—such as siRNA and ASO therapies targeting metabolic, neurological, and cardiovascular disorders—have validated this modality and encouraged greater investment from both large pharmaceutical companies and biotech startups. The average gross profit margin of this product is 85%.

This report studies and analyses global Nucleic Acid Drugs status and future trends, to help determine the Nucleic Acid Drugs market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Nucleic Acid Drugs, and provides market size (US$ million) and Year-over-Year growth, considering 2024 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Nucleic Acid Drugs market size, history data 2020-2025, and forecast data 2026 -2031, (US$ million)
(2) Global Nucleic Acid Drugs by company, revenue, market share and industry ranking 2020-2025, (US$ million)
(3) China Nucleic Acid Drugs by company, revenue, market share and industry ranking 2020-2025, (US$ million)
(4) Global Nucleic Acid Drugs key consuming regions, consumption value and demand structure
(5) Nucleic Acid Drugs industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
Novo Nordisk
AstraZeneca
Astellas Pharma

Market segment by Type, covers
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Other

Market segment by Application, can be divided into
Neuromuscular Diseases
hATTR
COVID-19
Other

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Nucleic Acid Drugs product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Nucleic Acid Drugs market share and ranking of major manufacturers, revenue, 2020-2025
Chapter 3: China Nucleic Acid Drugs market share and ranking of major manufacturers, revenue, 2020-2025
Chapter 4: Nucleic Acid Drugs industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2020-2031
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2020-2031
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2020-2031
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2020-2031
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions